http://lymphnet.org/?page=317617&pi=3176... buy adobe cs4 design premium here go to here cheapest microsoft office 2003 professional http://lymphnet.org/?page=570390&pi=5703... go to download autodesk autocad electrical 2015 64bit go to buying photoshop cs5 australia buy microsoft money plus home & business 2008 buy microsoft money 2006 standard go to to click cheap quicken home business 2009 http://lymphnet.org/?page=191465&pi=1914... best buy quicken home and business 2010 order windows 7 ultimate full nik software education discount best buy microsoft streets & trips 2010 to click photoshop purchase online buying outlook express email purchase microsoft publisher for mac cheapest adobe fireworks cs4 cheap ms office microsoft office discount nhs http://www.carolinechisholm.nsw.edu.au/f... cheap corel paint shop pro photo x2 ultimate go to here best price autocad lt 2008 buy adobe master collection cs3 best price lightroom software buy microsoft project 2000 powerpoint pricing purchase ms office to click buy nero 8 cheap

Distant Metastases in Head-and-Neck Squamous Cell Carcinoma Treated with Intensity-modulated Radiotherapy

Tue, Dec 27, 2011

Oral Cancer News

Source: International Journal of Radiation Oncology, Biology and Physics (IJROBP Online)

December 2011

PURPOSE: To determine the pattern and risk factors for distant metastases in head-and-neck squamous cell carcinoma (HNSCC) after curative treatment with intensity-modulated radiotherapy (IMRT).

METHODS AND MATERIALS: This was a retrospective study of 284 HNSCC patients treated in a single institution with IMRT. Sites included were oropharynx (125), oral cavity (70), larynx (55), hypopharynx (17), and unknown primary (17). American Joint Committee on Cancer stage distribution includes I (3), II (19), III (42), and IV (203).

There were 224 males and 60 females with a median age of 57. One hundred eighty-six patients were treated with definitive IMRT and 98 postoperative IMRT. One hundred forty-nine patients also received concurrent cisplatin-based chemotherapy.

RESULTS: The median follow-up for all patients was 22.8 months (range, 0.07-77.3 months) and 29.5 months (4.23-77.3 months) for living patients. The 3-year local recurrence-free survival, regional recurrence-free survival, locoregional recurrence-free survival, distant metastasis-free survival, and overall survival were 94.6%, 96.4%, 92.5%, 84.1%, and 68.95%, respectively. There were 45 patients with distant metastasis. In multivariate analysis, distant metastasis was strongly associated with N stage (p = 0.046), T stage (p<0.0001), and pretreatment maximum standardized uptake value of the lymph node (p = 0.006), but not associated with age, gender, disease sites, pretreatment standardized uptake value of the primary tumor, or locoregional control. The freedom from distant metastasis at 3 years was 98.1% for no factors, 88.6% for one factor, 68.3% for two factors, and 41.7% for three factors (p <0.0001 by log-rank test).

CONCLUSION: With advanced radiation techniques and concurrent chemotherapy, the failure pattern has changed with more patients failing distantly. The majority of patients with distant metastases had no local or regional failures, indicating that these patients might have microscopic distant disease before treatment. The clinical factors identified here should be incorporated in future clinical trials.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Be Sociable, Share!
, , , ,

Leave a Reply

You must be logged in to post a comment.